“Global Cutaneous Leishmaniasis Drugs Market By Product Type (Pentavalent Antimonials, Antifungal Drugs, Anti-Leishmanial/Antimicrobial Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies)), and Region- Global Market Size, Status and Forecast to 2026″, published by Verified Market Research.


The Global Cutaneous Leishmaniasis Drugs Market size is projected to grow from USD 40.5 Million in 2018 to USD 56.1 Million by 2026, at a CAGR of 4.23% from 2019 to 2026. Factors such as increasing healthcare spending is expected to support market growth during the forecast period. While per person healthcare spending has been observed to be varied region to region, global health care spending is projected to increase during the forecast period. According to the WHO, ‘spending on health is growing faster than the rest of the global economy, accounting for 10% of global gross domestic product (GDP).



Get | Download Sample Report @ – https://www.verifiedmarketresearch.com/download-sample/?rid=35353&utm_source=Free&utm_medium=004



Browse in-depth TOC on “Cutaneous Leishmaniasis Drugs Market”

50 – Tables
35 – Figures
84 – Pages



In terms of value, Anti-Leishmanial/Antimicrobial Drugs in the Product Type segment is estimated to be the fastest-growing type in the Cutaneous Leishmaniasis Drugs market in 2019.

Antileishmanial/ antimicrobial drugs are used in resistant to cutaneous leishmanias. The commonly used antileishmanial drugs include sodium antimony gluconate (SAG), amphotericin B, miltefosine and paromomycin. Amphotericin B is one of the most effective antileishmanial drugs as it induces high cure rates.

Pentavalent Antimonials account for the largest segment in the Product Type segment. Pentavalent antimonials are leishmania resistant drugs that have been isolated from dogs unresponsive to treatment. These drugs are known as first-line drugs against cutaneous leishmaniases, however, the treatment with these drugs can cause adverse effects and is not always effective.

An opportunity for growth in this market is the potential for a new line of treatment. Despite possibilities for treatment being available for the past couple of decades, treatment for Leishmaniasis such as chemotherapy, has shown a lack of efficiency, since its route of administration is difficult and it can cause serious side effects and can result in the emergence of resistant cases.

Get More Information @ – https://www.verifiedmarketresearch.com/download-sample/?rid=35353&utm_source=Free&utm_medium=004

On the basis of regional analysis, the Global Cutaneous Leishmaniasis Drugs market is classified into North America, Europe, Asia Pacific and Rest of the world.



North America accounted for the largest market share and is projected to grow at a CAGR of 4.16% during the forecast period.

In North America, leishmaniasis is commonly linked with the disease of travelers. The majority of the disease is observed from travel and immigration patterns across the region. In the United States, the majority of CL cases have been imported from Latin American countries. In 2015, the World Health Organization classified the United States as a leishmaniasis-endemic nation.



Key players



Knight Therapeutics, gland pharma, Sanofi, Novartis, GloxoSmithKline, Pfizer, Cheplapharm Arzneimittel GmbH and Jassen Pharmaceutical are the key players operating in the Cutaneous Leishmaniasis Drugs market. Acquisitions and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Cutaneous Leishmaniasis Drugs Market.



Obtain Report Details @ https://www.verifiedmarketresearch.com/press-release/cutaneous-leishmaniasis-drugs-market/?utm_source=Free&utm_medium=004